Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytoreductive surgery. Now, data from the phase III CHIPOR trial demonstrate that adding intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) improves overall survival (OS) in this setting.

In this trial, a total of 517 women with recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with disease recurrence ≥6 months after completion of chemotherapy received 6 cycles of preoperative platinum-doublet chemotherapy (with or without bevacizumab). The 415 patients deemed eligible for cytoreductive surgery were then randomly allocated 1:1 to receive surgery with versus without cisplatin HIPEC. OS was the primary end point.

晚期卵巢癌晚期复发的女性通常接受术前化疗，然后进行细胞减灭术。现在，来自 III 期 CHIPOR 试验的数据表明，在这种情况下，增加术中腹腔热灌注化疗 （HIPEC） 可提高总生存期 （OS）。

在该试验中，共有 517 名复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌女性在化疗完成后 6 个月≥接受了 6 个周期的术前铂类双药化疗（联合或不联合贝伐珠单抗）。然后将 415 例被认为适合细胞减灭术手术的患者随机分配 1：1 接受手术，有与没有顺铂 HIPEC。OS 是主要终点。